Patients n | FEV1/TLC % | MEF60%TLC %TLC·s−1 | MEF40%TLC %TLC·s−1 | |
Male children | ||||
BA+PL | 15 | −0.9±2.7 | −2.3±7.4 | −1.7±4.1 |
BA+ICS | 21 | −0.7±1.0 | −1.8±4.4 | −1.7±2.9 |
Female children | ||||
BA+PL | 5 | −0.9±2.5 | −0.2±6.3 | −1.9±5.3 |
BA+ICS | 13 | −0.1±1.9 | −1.6±6.9 | −0.6±5.2 |
ANOVA | ||||
Treatment | 0.40 | 0.81 | 0.01 | |
Sex | 0.64 | 0.55 | 0.30 |
Data are presented as means±sd unless otherwise indicated
BA+PL: β2‐agonist+placebo
BA+ICS: β2‐agonist+inhaled corticosteroids
FEV1: forced expiratory volume in one second
TLC: total lung capacity
MEF60%TLC, MEF40%TLC: maximum expiratory flow at 60% or 40% of TLC, respectively